紫杉醇联合洛铂在局部晚期宫颈癌患者术前新辅助化疗中的应用

Paclitaxel Combined with Lobaplatin in Neoadjuvant Chemotherapy for Patients with Locally Advanced Cervical Cancer

目的研究紫杉醇联合洛铂在局部晚期宫颈癌(LACC)患者术前新辅助化疗中的应用效果。方法选取2017年6月~2018年12月经我院病理确诊的LACC患者68例,按照随机数字表法分为两组,每组34例。对照组仅单纯采用经腹根治性子宫切除术治疗,观察组在术前予以紫杉醇联合洛铂的新辅助化疗方案治疗。比较两组临床疗效(疾病总缓解率)、治疗前后血清肿瘤标志物水平[血清细胞角蛋白19片段抗原21-1(CY-FRA21-1)、鳞状上皮癌抗原(SCCAg)]、不良反应发生情况、术后淋巴结转移及复发情况。结果观察组治疗后的CY-FRA21-1、SCCAg水平低于对照组,差异有统计学意义(P<0.05);观察组疾病总缓解率高于对照组,差异有统计学意义(P<0.05);观察组治疗后淋巴结转移率、复发率均低于对照组,差异有统计学意义(P<0.05);观察组化疗毒副反应轻微。结论对LACC患者采用紫杉醇联合洛铂的术前新辅助化疗方案疗效和安全性较好,有助于降低血清肿瘤标志物水平,减少术后淋巴结转移及复发情况。

Objective To study the effect of paclitaxel combined with Lobaplatin in neoadjuvant chemotherapy for patients with locally advanced cervical cancer(LACC).Methods A total of 68 patients with LACC diagnosed by pathology in our hospital from June 2017 to May 2018 were selected and divided into two groups according to the random number table method,34 cases in each group.The control group was only treated by radical abdominal hysterectomy,and the observation group was treated with neoadjuvant chemotherapy of paclitaxel combined with Lobaplatin before surgery.Comparison of clinical efficacy(total remission rate of the disease),serum tumor marker levels before and after treatment[serum cytokeratin 19 fragment antigen 21-1(CY-FRA21-1),squamous cell carcinoma antigen(SCCAg)],adverse reactions occurrence,postoperative lymph node metastasis and recurrence.Results The CY-FRA21-1 and SCCAg levels of the observation group after treatment were lower than the control group,the difference was statistically significant(P<0.05);the total disease remission rate of the observation group was higher than the control group,the difference was statistically significant(P<0.05);The lymph node metastasis rate and recurrence rate of the observation group after treatment were lower than that of the control group,the difference was statistically significant(P<0.05);the side effects of chemotherapy in the observation group were slight.Conclusion The preoperative neoadjuvant chemotherapy of paclitaxel combined with Lobaplatin in LACC patients has good efficacy and safety,which can help to reduce serum tumor marker levels and reduce postoperative lymph node metastasis and recurrence.